Lexeo Therapeutics, Inc. (LXEO)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

3.23 on 9 Oct 2026

0 buys20 sales at will1 planned sale

Fiscal year 2022, ended 31 Dec 2022, as filed

Revenue

$654.00K

Net income

$59.28M

Free cash flow

$55.23M

Operating margin

-9,252.1%

Net margin

-9,063.8%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
18 Aug 2026	Tamayo Louis Edward Chief Financial Officer	Sold at will	$20.20K	4.2%
18 Aug 2026	Townsend Richard Nolan Chief Executive Officer	Sold at will	$16.56K	0.9%
18 Aug 2026	Otero Jose Manuel Chief Operating Officer	Sold at will	$6.46K	0.9%
1 Jul 2026	Townsend Richard Nolan Chief Executive Officer	Sold at will	$116.24K	6.4%
1 Jul 2026	Bhalla Narinder Pal Chief Medical Officer	Sold at will	$98.59K	21.3%
1 Jul 2026	Otero Jose Manuel Chief Operating Officer	Sold at will	$20.90K	3.3%

11out of 100

Profitability 0

Financial strength 17

Growth n/a

Insiders 20

Strongest on insiders (20), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$978.40K

21 sales

Planned sales

under a 10b5-1 plan